Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

Xilio Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

RECEIVED FDA CLEARANCE OF IND APPLICATION FOR XTX501, A POTENTIAL BEST-IN-CLASS BISPECIFIC PD-1 / MASKED IL-2 ADVANCING IND-ENABLING STUDIES FOR POTENTIAL FIRST-IN-CLASS MULTI-SPECIFIC, MASKED T CELL ENGAGER PROGRAMS TARGETING CLDN18.2 AND PSMA+STEAP1; IND APPLICATIONS ANTICIPATED IN THE SECOND HALF OF 2027 CASH RUNWAY INTO THE FIRST QUARTER OF 2028 EXPECTED TO SUPPORT KEY MILESTONES ACROSS PIPELINE OF NEXT GENERATION MULTI-SPECIFIC I-O THERAPIES WALTHAM, MASS., AUG. 12, 2026 (GLOBE NEWSWIRE) -- XILIO THERAPEUTICS, INC. (NASDAQ: XLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DISCOVERING AND DEVELOPING MASKED IMMUNO-ONCOLOGY THERAPIES FOR PEOPLE LIVING WITH CANCER, TODAY ANNOUNCED PIPELINE PROGRESS AND BUSINESS UPDATES AND REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026.

XILIO THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES PIPELINE AND BUSINESS UPDATES

WALTHAM, MASS., JULY 06, 2026 (GLOBE NEWSWIRE) -- XILIO THERAPEUTICS, INC. (NASDAQ: XLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DISCOVERING AND DEVELOPING MASKED IMMUNO-ONCOLOGY THERAPIES FOR PEOPLE LIVING WITH CANCER, TODAY ANNOUNCED THAT, EFFECTIVE JULY 1, 2026, THE COMPANY GRANTED NON-QUALIFIED STOCK OPTIONS TO PURCHASE 107,060 SHARES OF ITS COMMON STOCK TO THREE NEW EMPLOYEES UNDER XILIO THERAPEUTICS' 2022 INDUCEMENT STOCK INCENTIVE PLAN.

XILIO THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

WALTHAM, MASS., JUNE 29, 2026 (GLOBE NEWSWIRE) -- XILIO THERAPEUTICS, INC. (NASDAQ: XLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DISCOVERING AND DEVELOPING MASKED IMMUNO-ONCOLOGY THERAPIES FOR PEOPLE LIVING WITH CANCER, TODAY ANNOUNCED THE APPOINTMENT OF BEN HARSHBARGER AS CHIEF LEGAL OFFICER.

Xilio Therapeutics, Inc.

XLO

Price

Financial Reports

No items found.

Press Releases

Xilio Therapeutics, Inc.

XLO.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

XLO